Better Context Better Decisions

Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.

european medicines agency cover image
$599
Posted in: Bolus Insulin, GLP-1RA, GLP-1RA + Basal, SGLT2i Feb 25 | 2020CREDENCE CHMP Opinion This Week? DAPA-HF Filed with EMA; CHMP Agenda February 24-27Purchase Blast
sanofi cover image
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery Feb 21 | 2020First Look at Sanofi's Connected Insulin Pen Solutions?Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Feb 20 | 2020FDA Issues Final Rule on Definition of "biological product"; ATTD 2020 Key Press Releases (Feb 20)Purchase Blast
astrazeneca cover image
$599
Posted in: Dual/triple agonist, GLP-1RA, SGLT2i Feb 14 | 2020AstraZeneca Q4 '19 Earnings UpdatePurchase Blast
dexcom cover image
$599
Posted in: Glucose Monitoring Feb 13 | 2020Dexcom Q4 '19 Earnings UpdatePurchase Blast
novo cover image
$599
Posted in: Dual/triple agonist Feb 07 | 2020New Novo GLP-1/GIP Ph1 Trial?Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist Feb 06 | 2020Novo Q4 '19 London Earnings; Sanofi and BD Q4 '19 Earnings UpdatesPurchase Blast
lilly cover image
$599
Posted in: Dual/triple agonist Feb 05 | 2020Tirzepatide CVOT Record Available on CT.govPurchase Blast
novo cover image
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon Feb 05 | 2020Positive Topline Novo QW Insulin Results; Novo Q4 '19 Earnings UpdatePurchase Blast
1 53 54 55 56 57 88

Get the Latest Analysis

Stay informed and aligned with frequent updates to keep a pulse on the industry.

If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.